Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
norvancomycin
- Development stage
- Phase 4
- Lead developer
- North China Pharmaceutical
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
Norvancomycin is a glycopeptide antibiotic closely related to vancomycin, differing by a single methyl group. It was first isolated from Amycolatopsis orientalis and has been used clinically in China since the late 1960s. Norvancomycin acts by inhibiting bacterial cell wall synthesis, making it effective against resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Its primary indications include severe infections such as endocarditis, osteomyelitis, pneumonia, sepsis, and soft tissue infections caused by susceptible organisms. Norvancomycin is typically administered intravenously[1][2][5][7].
- Brand names
- norvancomycin
- Other names
- desmethylvancomycin56-demethylvancomycin
02
Targets
D-Ala-D-Ala (D-Ala-D-Ala terminus)
Beyond the preview
Go deeper on norvancomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on norvancomycin.